C. Ng

Most-cited papers

1. Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial

   C. Ng, R. Bruno, D. Combs, B. Davies

   2005Journal of clinical pharmacology208 citations

   Semantic Scholar

   Save

2. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples

   R. Bauer, S. Guzy, C. Ng

   2007AAPS Journal201 citations Open access

   Semantic Scholar

   Save

3. Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

   A. Ricart, A. Tolcher, Glenn Liu, K. Holen +6 more

   2008Clinical Cancer Research157 citations Open access

   Semantic Scholar

   Save

4. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis

   Xiao-Cong Zuo, C. Ng, J. Barrett, Ai-Jing Luo +15 more

   2013Pharmacogenetics & Genomics136 citations

   Semantic Scholar

   Save

5. Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis

   C. Ng, B. Lum, Verónica Giménez, S. Kelsey +1 more

   2006Pharmaceutical Research106 citations

   Semantic Scholar

   Save

6. Pharmacokinetics/Pharmacodynamics of Nondepleting Anti-CD4 Monoclonal Antibody (TRX1) in Healthy Human Volunteers

   C. Ng, E. Stefanich, Banmeet S. Anand, P. Fielder +1 more

   2006Pharmaceutical Research105 citations

   Semantic Scholar

   Save

7. Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis

   C. Ng, A. Joshi, R. Dedrick, M. Garovoy +1 more

   2005Pharmaceutical Research85 citations

   Semantic Scholar

   Save

8. Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

   C. Takimoto, M. Graham, G. Lockwood, C. Ng +13 more

   2007Clinical Cancer Research72 citations Open access

   Semantic Scholar

   Save

9. Quantitative structure-pharmacokinetic parameters relationships (QSPKR) analysis of antimicrobial agents in humans using simulated annealing k-nearest-neighbor and partial least-square analysis methods.

   C. Ng, Yun-De Xiao, W. Putnam, B. Lum +1 more

   2004Journal of Pharmacy and Science49 citations

   Semantic Scholar

   Save

10. Use of Quantitative Pharmacology in the Development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody

    W. Putnam, Jing Li, J. Haggstrom, C. Ng +8 more

    2008AAPS Journal47 citations Open access

    Semantic Scholar

    Save

11. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer

    J. Rodón, A. Patnaik, M. Stein, A. Tolcher +6 more

    200740 citations

    Semantic Scholar

    Save

12. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts

    Edna F. Choo, C. Ng, L. Berry, M. Belvin +3 more

    2012Cancer Chemotherapy and Pharmacology32 citations

    Semantic Scholar

    Save

13. Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients

    C. Ng, S. Bai, C. Takimoto, M.-T. Tang +1 more

    2009Cancer Chemotherapy and Pharmacology32 citations

    Semantic Scholar

    Save

14. Rational Clinical Dose Selection of Adeno‐Associated Virus‐Mediated Gene Therapy Based on Allometric Principles

    Fei Tang, H. Wong, C. Ng

    2021Clinical pharmacology and therapy29 citations

    Semantic Scholar

    Save

15. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.

    C. Ng, K. Loyet, S. Iyer, P. Fielder +1 more

    2014European Journal of Pharmaceutical Sciences29 citations

    Semantic Scholar

    Save

16. The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab.

    Benjamin Wu, A. Joshi, S. Ren, C. Ng

    2006Journal of Pharmacy and Science27 citations

    Semantic Scholar

    Save

17. Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys

    D. Lu, Jin Y. Jin, S. Girish, P. Agarwal +8 more

    2014Pharmaceutical Research24 citations Open access

    Semantic Scholar

    Save

18. Quantitative structure-activity relationships of methotrexate and methotrexate analogues transported by the rat multispecific resistance-associated protein 2 (rMrp2).

    C. Ng, Yun-De Xiao, B. Lum, Yong-Hae Han

    2005European Journal of Pharmaceutical Sciences24 citations

    Semantic Scholar

    Save

19. Population pharmacokinetics of exendin‐(9‐39) and clinical dose selection in patients with congenital hyperinsulinism

    C. Ng, Fei Tang, S. Seeholzer, Yixuan Zou +1 more

    2018British Journal of Clinical Pharmacology17 citations Open access

    Semantic Scholar

    Save

20. Incorporation of FcRn‐mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients

    C. Ng

    2016Biopharmaceutics & drug disposition13 citations

    Semantic Scholar

    Save

21. Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients

    C. Ng, A. Patnaik, M. Beeram, C. Lin +1 more

    2011Cancer Chemotherapy and Pharmacology11 citations

    Semantic Scholar

    Save

22. Pharmacokinetics (PK) of pertuzumab (rhuMAb 2C4) in phase II studies of ovarian, breast, prostate, and lung cancers

    D. E. Allison, C. Ng, M. Derynck, S. Lutzker +2 more

    200510 citations

    Semantic Scholar

    Save

23. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey

    C. Ng, P. Fielder, Jin Y. Jin, R. Deng

    2016AAPS Journal9 citations

    Semantic Scholar

    Save

24. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors

    J. Rodón, A. Patnaik, M. Stein, A. Tolcher +6 more

    20079 citations

    Semantic Scholar

    Save

25. Validation of a HPLC/MS Method for Simultaneous Quantification of Clonidine, Morphine and its Metabolites in Human Plasma

    Fei Tang, H. Bada, C. Ng, M. Leggas

    2019Biomedical chromotography7 citations Open access

    Semantic Scholar

    Save

26. Comparison of Neural Network, Bayesian, and Multiple Stepwise Regression‐Based Limited Sampling Models to Estimate Area Under the Curve

    C. Ng

    2003Pharmacotherapy3 citations

    Semantic Scholar

    Save

27. A Modified Hybrid Wald’s Approximation Method for Efficient Covariate Selection in Population Pharmacokinetic Analysis

    Yixuan Zou, Fei Tang, C. Ng

    2021AAPS Journal2 citations

    Semantic Scholar

    Save

28. Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer

    Yixuan Zou, Fei Tang, J. Talbert, C. Ng

    2020PLoS ONE2 citations Open access

    Semantic Scholar

    Save

29. Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors

    Fei Tang, E. Tsakalozou, S. Arnold, C. Ng +1 more

    2019Investigational new drugs2 citations Open access

    Semantic Scholar

    Save

30. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies

    Chia-Chi Lin, M. Beeram, E. Rowinsky, C. Takimoto +9 more

    2009Cancer Chemotherapy and Pharmacology2 citations Open access

    Semantic Scholar

    Save

31. Assessment of dose response information in drug labeling

    D. A. Spyker, P. Frohna, P. Kuebler, S. Kelsey +10 more

    20042 citations

    Semantic Scholar

    Save

32. Quantitative Pharmacology Approach to Select Optimal Dose and Study the Important Factors in Determining Disposition of Therapeutic Monoclonal Antibody in Pediatric Subjects - Some Considerations

    D. Hardiansyah, C. Ng

    2019Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases1 citations

    Semantic Scholar

    Save

33. Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys

    D. Lu, Jin Y. Jin, S. Girish, P. Agarwal +8 more

    2014Pharmaceutical Research0 citations Open access

    Semantic Scholar

    Save

34. [Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine].

    Xiao-Cong Zuo, Hong Yuan, Bi-Kui Zhang, C. Ng +8 more

    2012Yao xue xue bao = Acta pharmaceutica Sinica0 citations

    Semantic Scholar

    Save

35. Semi-physiological pharmacokinetic-pharmacodynamic (PK/PD) models for troxacitabine-induced neutropenia and thrombocytopenia

    C. Ng, B. Muralidhar, C. Takimoto, C. Lin +1 more

    20070 citations

    Semantic Scholar

    Save

36. F.40. Relationship Between Clinical Response, Rituximab (Rtx) Pharmacokinetics, and Peripheral B-Cell Levels in Rheumatoid Arthritis (RA)

    F. Breedveld, S. Agarwal, M. Yin, C. Ng +3 more

    20060 citations

    Semantic Scholar

    Save

37. POPULATION PHARMACOKINETICS OF RITUXIMAB IN RA PATIENTS: COMBINING TWO PHASE II STUDIES PAGE 2005

    M. Levi, C. Ng, J. Gries, B. Davies

    20050 citations

    Semantic Scholar

    Save

38. Administering fixed doses of her-antibody

    Дэвид Е. Эллисон, Рене Брюно, Цзянь-Фын Лу, Цзянь-Фын Лу +1 more

    20050 citations

    Semantic Scholar

    Save

39. Introduction of fixed doses of her-antibodies

    Дэвид Е. Эллисон, Рене Брюно, Цзянь-Фын Лу, C. Ng

    20050 citations

    Semantic Scholar

    Save

40. Rationale for fixed dosing of pertuzumab by population pharmacokinetic (POP PK) modeling

    C. Ng, B. Lum, S. Kelsey, V. Hersberger-Gimenez +1 more

    20050 citations

    Semantic Scholar

    Save